PARIS, France—Investigators designing ISAR-REACT 5, the first head-to-head trial of ticagrelor and prasugrel in ACS patients heading for revascularization, expected to prove that ticagrelor is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback